Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE-ALPORT
NCT06499948Phase 4Completed
- Start
- Feb 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin and spironolactone in Alport syndrome (2 arms). Primary endpoint: Change in 24-hours urine albumin-to-creatinine ratio at 24 weeks. Started Feb 2024; status: completed.
02
Drugs
dapagliflozinspironolactone
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on NCT06499948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06499948.